ABBV/ENTA’s 54% share of worldwide 4Q18 HCV sales (from ABBV or GILD) will hold roughly constant in 2019, according to the 2019 HCV sales guidance given by ABBV ($3.3B) and GILD ($2.7-2.9B).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”